<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Thursz, Mark Richard</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Prednisolone but Not PTX Improves 28-Day Mortality in Patients with Alcoholic Hepatitis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-11</style></pages><abstract><style  face="normal" font="default" size="100%">Severe alcoholic hepatitis, has a 28-day mortality rate of about 35%. Clinical trials have shown both corticosteroids and pentoxifylline (PTX) to be of potential therapeutic benefit, however, both are controversial. This article discusses data from the Steroids or Pentoxifylline for Alcoholic Hepatitis trial [STOPAH; ISRCTN88782125].</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>